Promoter holding
64.27%
CL
Cipla Limited - Due diligence report
A 360° intelligence report on Cipla: trust score, financial health, credit view, compliance, directors, growth and distress signals - genera…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cipla — 360° Intelligence Report
Generated from MCA filings & public records80/100
Trust Score
Low Risk
Cipla is assessed as Low Risk with a Trust Score of 80/100. Cipla is an active public limited indian non-government company incorporated in 1935, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 03 Jul 2026 from the latest processed filings. Cipla Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreCaution Indicated
35/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (AAA).
Charges position: 0 open (-) · 1 satisfied (68.50 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Hongkong And Shanghai Banking Corporation Limited (Lead Charge Holder) | 1 | 48.0 cr |
Compliance Score: 80/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 4 court forum(s).
- 30 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 35/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| KAMIL HAMIED | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YUSUF HAMIED KHWAJA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMESH PRATHIVADIBHAYANKARA RAJAGOPALAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ABHIJIT JAGDISH JOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| UMANG VOHRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHARMILA NITIN PARANJPE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANDAR PURUSHOTTAM VAIDYA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHISH ADUKIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Balram Bhargava | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ADIL ZAINULBHAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ROBERT STEWART | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAYA HARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rajendra Kumar Chopra | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 13 directors on the board.
- UMANG VOHRA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- 4 director exits in 3 years - high churn.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
6
Group entities
13
Capital events
87 allotment(s) · 2 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Cipla Digital Health Limited | Subsidiary Company | 74.00% |
| Cipla Health Limited | Subsidiary Company | 74.00% |
| Cipla Pharma And Life Sciences Limited | Subsidiary Company | 74.00% |
| Cipla Pharmaceutical S Limited | Subsidiary Company | 74.00% |
| Goldencross Pharma Limited | Subsidiary Company | 74.00% |
| Medispray Laboratories Private Limited | Subsidiary Company | 74.00% |
| Meditab Specialities Limited | Subsidiary Company | 74.00% |
| Sitec Labs Limited | Subsidiary Company | 74.00% |
| Jay Precision Pharmaceutical S Private Limited | Subsidiary Company | 74.00% |
| Stempeutics Research Private Limited | Associate Company | 74.00% |
Key managerial personnel: UMANG VOHRA (Managing Director) · ASHISH ADUKIA (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 80
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
EPFO headcount growing - hiring signal.
Operating for 90+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
3 director exits within 2 years.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment91/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view87/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events16 Jul 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
01 Nov 2024
Director appointed
KAMIL HAMIED (Director)
Director appointed
MAYA HARI (Director)
Director ceased
MAYA HARI
12 Oct 2024
Director ceased
ABHIJIT JAGDISH JOSHI
Director ceased
SHARMILA NITIN PARANJPE
03 Sep 2024
Director appointed
ABHIJIT JAGDISH JOSHI (Director)
01 Sep 2024
Director appointed
SHARMILA NITIN PARANJPE (Director)
15 May 2024
Director ceased
Balram Bhargava
01 Apr 2024
Director appointed
Balram Bhargava (Director)
21 Dec 2022
Securities allotted
61603 Equity Shares - 1.23 Lakh raised
Securities allotted
4133 Equity Shares - 8,266.00 raised
21 Nov 2022
Securities allotted
21975 Equity Shares - 43,950.00 raised
Securities allotted
1960 Equity Shares - 3,920.00 raised
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
13 active director(s) / partner(s); review board churn before relying on management continuity.
30 active GST registration(s) indicate ongoing business operations.
All 1 registered charge(s) stand satisfied - past borrowings repaid.
Operates a group structure with 6 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of AAA from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 87 security allotment(s) - amounts available in the full report.
54 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Pidilite | L24100MH1969PLC014336 | Mumbai, Maharashtra, India |
| Paradeep Phosphates | L24129OR1981PLC001020 | Bhubaneswar, Orissa, India |
| Polychem | L24100MH1955PLC009663 | Mumbai, Maharashtra, India |
| Zydus Lifesciences | L24230GJ1995PLC025878 | Ahmedabad, Gujarat, India |
| Rashtriya Chemicals And Fertilizers | L24110MH1978GOI020185 | Mumbai- 400 022., Maharashtra, India |
| Sunpharma | L24230GJ1993PLC019050 | Vadodara, Gujarat, India |
| Coromandel | L24120TG1961PLC000892 | Andhra Pradesh, Telangana, India |
| Grasim | L17124MP1947PLC000410 | Ujjain, Madhya Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cipla before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cipla: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Cipla - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Cipla pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Cipla - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cipla an active company?
Cipla has MCA status “Active” with a compliance score of 80/100 (Low Risk).
Is Cipla financially healthy?
Cipla has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Cipla?
Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cipla?
Promoters hold a minority stake - exact percentages are in the full report. 13 active director(s) are on record.
Does Cipla have loans or charges against its assets?
No open charges - all 1 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Cipla up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 80/100 (Low Risk).
Is it risky to lend to Cipla?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
